title: Autoimmune Cardiotoxicity of Cancer Immunotherapy.
abstract: Contemporary immunotherapies (e.g., immune checkpoint inhibitors), which enhance the immune response to cancer cells, improve clinical outcomes in several malignancies. A recent study reported the cases of two patients with metastatic melanoma who developed fatal myocarditis during ipilimumab and nivolumab combination immunotherapy; these examples highlight the risk of unbridled activation of the immune system.
authors.affiliation: Center for Complex Networks Research, Northeastern University, Boston, MA 02115, USA; Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: fxcheng1985@gmail.com.
authors.forename: Feixiong
authors.initials: F
authors.lastname: Cheng
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: jloscalzo@partners.org.
authors.forename: Joseph
authors.initials: J
authors.lastname: Loscalzo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000209:etiology / Q000276:immunology*; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D000074324:Ipilimumab; D009205:Myocarditis / Q000209:etiology / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000077594:Nivolumab; D012306:Risk
chemical_list: D000911:Antibodies, Monoclonal; D061025:Costimulatory and Inhibitory T-Cell Receptors; D000074324:Ipilimumab; D000077594:Nivolumab
keywords: cardio-oncology; immune checkpoint; immunotherapy.; ipilimumab; nivolumab